STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #661 by analyst upside · 2026-09-10
TYRA
Tyra Biosciences, Inc.
Healthcare · Market Cap $1B · P/E 0x
ANALYST PRICE TARGET
+130.9%
implied upside to consensus target
Current Price $22.01
Consensus Target $50.82
Bull Target $59.0
Bear Target $39.0
Analysts Covering 11
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
9
Hold
1
Sell
0
52-Week Low $11.7
52-Week High $40.65
YTD Return -17.8%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.39
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $11.7
52-Week High $40.65
Current Price $22.01
Bear Target $39.0
Bull Target $59.0
● Now $22.01 ● Target $50.82
TRADING DATA
Avg Volume 828K
YTD Return -17.8%
Analyst Count 11
Consensus Buy
Upside to Target +130.9%
Last Updated 2026-09-10

ANALYST SUMMARY

Tyra Biosciences, Inc. (TYRA) is currently trading at $22.01 with a Wall Street consensus price target of $50.82, implying potential upside of 130.9% over the next 12 months. 11 analysts currently cover TYRA, with a consensus rating of Buy - 91% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $59.0, while the most cautious has a target of $39.0.

TYRA operates in the Healthcare sector with a market capitalisation of $1B. The stock is down 17.8% year-to-date and is currently trading near the lower end of its 52-week range of $11.7 – $40.65.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TYRA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-09-04 31% win rate (48 calls)
Jones Trading ● Initiated
Buy 2026-06-17 57% win rate (14 calls)
B of A Securities - Reiterated
Buy → Buy 2026-06-10 Building track record
Wolfe Research ● Initiated
Peer Perform 2026-05-19 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-05-14 31% win rate (48 calls)
Guggenheim ● Initiated
Buy 2026-04-15 62% win rate (8 calls)
Canaccord Genuity ● Initiated
Buy 2026-04-06 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2026-03-20 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
53
out of 100
Coverage depth
19/30
Consensus clarity
12/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →